Skip to content
Bomb Report – Lifestyle
Author:
HUTCHMED (China) Limited
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
March 7, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates
March 6, 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
March 6, 2026
←
Previous Page
1
2